Nervous System Diseases

At Filadelfia, the clinical research focus is centered on Nervous System Diseases, with studies aimed at improving care for people living with difficult-to-control epilepsy. The site is part of the Danish Epilepsy Center in Dianalund, and its trials are designed to assess whether new treatments can better manage seizure burden while remaining safe and tolerable.

  • Research in epilepsy and related neurological conditions
  • Studies for refractory focal onset epilepsy in adults
  • Evaluation of new options to improve seizure control and overall treatment benefit

The work at this hospital reflects a practical effort to test emerging therapies for people whose seizures are not adequately controlled by current treatment.

Refractory Focal Onset Epilepsy

One major area of research at this site involves refractory focal onset epilepsy, a form of epilepsy that remains challenging despite standard treatment. The trials are focused on evaluating whether new therapies can reduce seizure frequency and provide meaningful support for adults affected by this condition.

  • Testing the safety and tolerability of a new therapy
  • Comparing treatment benefit against placebo to understand effectiveness
  • Measuring whether patients achieve fewer seizures over time

These studies are intended to help clarify whether investigational treatments may offer better seizure management for adults treated at Filadelfia.

Dravet Syndrome

Another important research focus is Dravet Syndrome, a severe neurological disorder associated with frequent seizures in both children and adults. The studies at this site are evaluating whether new treatment approaches can reduce motor seizures and improve disease control for people living with this complex condition.

  • Research in epilepsy care for Dravet Syndrome
  • Assessment of a potential new therapy for seizure reduction
  • Efforts to improve treatment effectiveness in a difficult neurological disease

This work supports the broader goal of finding more effective options for patients who need better long-term control of seizures.